Cabaletta Bio Inc.
Engineered T cell therapies designed for the treatment of patients with autoimmune diseases
- Location
- —
- Roles tracked
- 0
- In pipeline
- 0
- Tracking since
- —
At a glance
You're tracking 0 roles at Cabaletta Bio Inc.. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync- Industry
- Biotechnology Research
- Company size
- 201 people
- Headquarters
- Philadelphia, Pennsylvania
- Founded
- 2017
- Type
- Public Company
- Total funding
- $460.0M
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
